Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:TEM News 8 October 2025 - 6 December 2025

Tempus AI (TEM) Stock: FDA Wins, Q3 Earnings, and Analyst Forecasts – December 6, 2025

Tempus AI (TEM) Stock: FDA Wins, Q3 Earnings, and Analyst Forecasts – December 6, 2025

Updated: December 6, 2025 Tempus AI Inc. (NASDAQ: TEM) has quickly become one of the most closely watched artificial intelligence stocks in healthcare. After a year marked by multiple FDA clearances, strong revenue growth and high-profile partnerships, Wall Street is now debating whether the current share price in the mid‑$70s still leaves meaningful upside. Business Wire+1 Fresh research notes and news items published on December 5–6, 2025—including new institutional buying, updated growth forecasts and a cluster of analyst price targets—are reshaping the conversation around the stock’s outlook heading into 2026. MarketBeat+2Nasdaq+2 Tempus AI at a glance Tempus AI is a
6 December 2025
··
Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – Inside the Price Surge, Latest News & 2025 Outlook

Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – Inside the Price Surge, Latest News & 2025 Outlook

Stock Price Surge: From IPO to Record Highs Tempus AI’s stock has been on a remarkable tear since its mid-2024 IPO. The Chicago-based healthtech firm – founded in 2015 by Eric Lefkofsky (of Groupon fame) – went public in June 2024 at around $21 per share, and the price has since quadrupled ts2.tech. After a steady climb through 2024, momentum accelerated in 2025 as the company delivered strong results and AI breakthroughs. By early September 2025, TEM had more than doubled its IPO price, reaching the high-$80s to $90 range ts2.tech. A series of catalysts (detailed below) then propelled the
9 October 2025
·
Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know

Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know

Company Overview and Mission Tempus AI, Inc. is an American health technology company founded in 2015 by entrepreneur Eric Lefkofsky (best known as co-founder of Groupon). Headquartered in Chicago, Tempus was born from Lefkofsky’s personal mission to improve cancer care after his wife’s battle with breast canceren.wikipedia.org. The company’s core focus is on applying AI and data analytics to personalized medicine. Tempus has built what it calls an “operating system” for healthcare: a platform that ingests vast amounts of clinical and molecular data (gene sequences, lab tests, medical records, imaging, etc.) and makes it accessible for treatment decisions and researchinsidermonkey.com. Its goal is to enable doctors and
8 October 2025
···

Stock Market Today

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company projected about $200 billion in 2026 capital expenditures, triggering investor concern over AI spending. The stock had already dropped 11.5% after-hours Thursday. Amazon forecast Q1 net sales of $173.5–$178.5 billion and operating income of $16.5–$21.5 billion. Analyst Gil Luria downgraded Amazon, citing rising investment as its cloud lead narrows.
AMD stock jumps 8% in chip rebound — what investors are watching before Monday

AMD stock jumps 8% in chip rebound — what investors are watching before Monday

7 February 2026
AMD shares jumped 8.2% to $208.44 Friday, trading on heavy volume as chip stocks rebounded and the Dow closed above 50,000 for the first time. The Philadelphia Semiconductor Index rose 5.7% after Amazon’s AI spending plans lifted sector estimates. Nvidia’s CEO cited surging AI chip demand. AMD’s rally followed a weak revenue outlook earlier in the week.
Go toTop